Reconstitution chart: 10 mg vial
| BAC water added | Concentration | Draw for 1 mg dose | Draw for 2 mg dose |
|---|---|---|---|
| 1 mL | 10,000 mcg/mL | 10 units | 20 units |
| 1.5 mL | 6,667 mcg/mL | 15 units | 30 units |
| 2 mL | 5,000 mcg/mL | 20 units | 40 units |
| 2.5 mL | 4,000 mcg/mL | 25 units | 50 units |
Draws are U-100 insulin syringe units (100 units = 1 mL). Formula: dose in mcg ÷ (vial mcg ÷ water mL) × 100. The calculator above handles any other combination.
About Retatrutide
Retatrutide is an investigational triple agonist from Eli Lilly that targets the GIP, GLP-1, and glucagon receptors at once. It is NOT approved by the FDA or any other regulator. It is still in phase 3 clinical trials, which means there is no approved product, no official dosing schedule, and no established long-term safety profile. Every retatrutide vial in circulation outside a trial is gray-market material.
Demand exploded after the phase 2 results published in 2023 reported larger average weight loss than anything approved at the time. In those trials, participants were titrated from low starting doses up to a range of roughly 1 mg to 12 mg once weekly, always under medical supervision and always stepwise. Because no approved schedule exists, this page makes no dosing suggestion at all. The presets above are common round numbers, nothing more.
Retatrutide has a half-life of roughly 6 days in published trial data, consistent with once-weekly injection. Vials commonly circulate in 5, 10, and 15 mg sizes. The same unit arithmetic applies as with any lyophilized peptide: the water you add sets the concentration, and the concentration sets your draw. Be extra careful here precisely because there is no label to check yourself against.
Quick facts
- Status: investigational, phase 3 trials, NOT approved anywhere
- Half-life: roughly 6 days in published trial data
- Trial dosing ran from about 1 mg to 12 mg weekly, titrated under supervision
- Common gray-market vial sizes: 5, 10, and 15 mg